文献速递中医内科中药与中成药合理使用

中药联合西医治疗重度至极重度慢阻肺的多中心随机双盲对照研究

Effect of traditional Chinese medicine combined with conventional Western medicine for patients with severe/very severe chronic obstructive pulmonary disease: a multi-center, randomized, double-blind, controlled study.
PubMed 文献 · Chin Med · 2025-05-20

本研究为多中心随机双盲安慰剂对照试验,纳入稳定期重度至极重度COPD患者467例,在常规西医治疗基础上加用辨证中药颗粒(补肺健脾、补肺益肾、益气滋肾),治疗12个月并随访12个月。结果显示中药组急性加重次数减少,mMRC评分、6MWT和CAT评分改善,但肺功能指标FVC和FEV1无显著差异。

要点

  • 辨证中药联合西医可减少重度慢阻肺急性加重次数(0.63 vs 1.03次,P=0.002)。
  • 中药组mMRC评分改善-0.17分(95%CI -0.30至-0.03,P=0.015)。
  • 中药组6MWT提高29.24米(95%CI 10.71-47.77,P=0.002),CAT改善-3.11分(P<0.001)。

核心结论

  • 基于中医证型的综合治疗对重度至极重度COPD患者有效,可减少急性加重、改善呼吸困难和运动能力、缓解症状。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,纳入稳定期重度至极重度COPD患者467例(试验组228例,对照组239例)。

主要发现

  • 中药颗粒组急性加重次数为0.63次,对照组为1.03次(P=0.002)。
  • 中药组mMRC评分改善-0.17分(95%CI -0.30至-0.03;P=0.015)。
  • 中药组6MWT提高29.24米(95%CI 10.71-47.77;P=0.002)。
  • 中药组CAT评分改善-3.11分(95%CI -4.13至-2.09;P<0.001)。
  • 两组FVC(升)和FEV1(升及百分比)无显著差异。

临床怎么用

  • 对稳定期重度至极重度COPD患者,可在常规西医治疗基础上加用辨证中药颗粒(补肺健脾、补肺益肾、益气滋肾)以减少急性加重并改善症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traditional Chinese medicine (TCM) is widely used in the management of chronic obstructive pulmonary disease (COPD). This study aimed to evaluate the clinical efficacy of comprehensive therapy based on TCM patterns for patients with stable, severe to very severe COPD. METHODS: A multicenter, randomised, double-blind, placebo-controlled trial was conducted. Eligible patients were randomly allocated in equal proportions to two groups: the trial group, which received TCM-based therapy with Bu-Fei Jian-Pi, and Bu-Fei Yi-Shen, and Yi-Qi Zi-Shen granules tailored to TCM syndromes, and the control group, which received a placebo resembling Chinese medicine. Both groups also received conventional Western medicine as part of their treatment. Acute exacerbations (AEs), lung function, dyspnea scores, the 6-min walking test (6MWT), and the COPD assessment test (CAT) were assessed over 12 months of treatment, with an additional 12 months of follow-up. RESULTS: A total of 467 patients were included in the analysis with 228 in the experimental group and 239 in the control group. The Chinese herbal granules group significantly reduced AEs (0.63 vs. 1.03 events, P = 0.002), improved mMRC scores (-0.17 points, 95% CI -0.30 to -0.03; P = 0.015), 6MWT (29.24 m, 95% CI 10.71-47.77; P = 0.002), and CAT (-3.11 points, 95% CI -4.13 to -2.09, P < 0.001), compared with the control group. No significant differences were observed between the two groups in terms of FVC (l) and FEV1 (both in litres and as percentage). CONCLUSION: Comprehensive therapy based on TCM patterns demonstrated efficacy in patients with severe to very severe COPD, reducing the frequency of AEs, improving dyspnea and exercise capacity, and alleviating symptoms. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02270424. Registered 17 October 2014, https://clinicaltrials.gov/study/NCT02270424?id=NCT02270424&rank=1 .

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Li J, Xie Y, Wang M, et al. Effect of traditional Chinese medicine combined with conventional Western medicine for patients with severe/very severe chronic obstructive pulmonary disease: a multi-center, randomized, double-blind, controlled study. Chin Med. 2025. PMID: 40394700. doi:10.1186/s13020-025-01117-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。